Reporting of harms in clinical trials of esketamine in depression: a systematic review.
Sign Up to like & getrecommendations! Published in 2023 at "Psychological medicine"
DOI: 10.1017/s0033291723001058
Abstract: While previous systematic reviews of trials evaluating conventional antidepressants highlighted inadequacies and inconsistencies in adverse event (AE) reporting, no evaluation is available on esketamine in resistant depression. The objective of this review was to assess… read more here.
Keywords: quality; clinical trials; trials esketamine; reporting harms ... See more keywords
Intranasal esketamine for depression: Not so special K
Sign Up to like & getrecommendations! Published in 2022 at "Australasian Psychiatry"
DOI: 10.1177/10398562221093870
Abstract: Background Intranasal esketamine has been recently approved for the treatment of resistant depression. It is the only form of ketamine approved. The formulation costs around $600 per dose while plain injected ketamine, on which most… read more here.
Keywords: depression special; intranasal esketamine; esketamine; esketamine depression ... See more keywords